title: [Clinical and metabolic effects of drospirenone-estradiol versus tibolone in postmenopausal women:a comparative study].
abstract: OBJECTIVE
  To compare the clinical and metabolic effects of drospirenone-estradiol (Angeliq) versus tibolone (Livial) in postmenopausal women.
  
  
  METHODS
  Twenty-seven postmenopausal women of group 1 took Angeliq (1 dose every two days) while another group 2 (n = 26) received tibolone (2.5 mg every two days) as hormone replacement therapy for 12 weeks. A retrospective analysis was used to evaluate the clinical efficacy, safety and risk factors of cardiovascular metabolism. The clinical data were collected before and after treatment, including personal interview, medical examination and ultrasound imaging of pelvic, breast and carotid artery.
  
  
  RESULTS
  No statistically significant inter-group differences existed in age or body mass index. Before treatment, the level of E2 was (12 ± 10) ng/L, triglyceride (TG) (2.0 ± 1.1) mmol/L, lipoprotein-a (LPa) (47 ± 43) mmol/L in group 1 versus (23 ± 12) ng/L, (1.3 ± 0.7) mmol/L and (28 ± 14) mmol/L in group 2. After 12-week treatment, (30 ± 18) ng/L, (1.6 ± 1.1) mmol/L and (37 ± 36) mmol/L in group 1 versus (23 ± 9) ng/L, (1.1 ± 0.6) mmol/L and (18 ± 12) mmol/L in group 2. A greater incidence of vaginal bleeding and thicker endometrium were found in group 1.
  
  
  CONCLUSIONS
  Angeliq can relieve menopausal symptoms. And its functions of regulating lipid metabolism and protecting cardiovascular system are better than those of Livial. However, its wider acceptability is limited by vaginal bleeding, thicker endometrium and breast pain.
authors.affiliation: Department of Obstetrics & Gynecology, Beijing Chaoyang Hospital, Beijing 100020, China; Email: annycheng2011@163.com.
authors.forename: Jiao
authors.initials: J
authors.lastname: Cheng
authors.affiliation: Department of Obstetrics & Gynecology, Beijing Chaoyang Hospital, Beijing 100020, China.
authors.forename: Zhenyu
authors.initials: Z
authors.lastname: Zhang
mesh_terms: D000736:Androstenes; D004338:Drug Combinations; D004958:Estradiol; D020847:Estrogen Receptor Modulators; D005260:Female; D006801:Humans; D009652:Norpregnenes; D017698:Postmenopause; D012189:Retrospective Studies; D014592:Uterine Hemorrhage
chemical_list: D000736:Androstenes; D004338:Drug Combinations; D020847:Estrogen Receptor Modulators; D009652:Norpregnenes; C488382:estradiol-drospirenone combination; D004958:Estradiol; C027385:tibolone; C035144:drospirenone